Banner Image Banner Image

Investors
& Media

Press Releases

Press Releases

All Releases
TG Therapeutics Announces Publication in Blood Advances Describing Unique Immunomodulatory Effects on CLL T cells by Umbralisib
NEW YORK , July 08, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of preclinical data describing the unique immunomodulatory effects of umbralisib, the Company’s investigational oral once-daily dual inhibitor of PI3K-delta and CK1-epsilon, in Blood
Jul 08, 2020
TG Therapeutics Announces Preclinical Data Presentation at the 2020 American Association for Cancer Research Annual Meeting
NEW YORK , June 22, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced preclinical data presentation for TG-1701, the Company’s highly selective, BTK inhibitor, at the 2020 American Association for Cancer Research (AACR) annual meeting, being held virtually. Michael S.
Jun 22, 2020
TG Therapeutics Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma or Follicular Lymphoma
NEW YORK , June 17, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics , Inc. (NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases, today announced the completion of the rolling submission of a New Drug Application (NDA) to the U.S.
Jun 17, 2020
TG Therapeutics to Present at the Raymond James 2020 Human Health Innovation Conference
Presentation scheduled for Thursday, June 18, 2020, at 3:40 PM ET NEW YORK , June 16, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss , the Company’s Executive Chairman and Chief Executive Officer, will present at the Raymond James 2020 Human
Jun 16, 2020
TG Therapeutics Announces Data Presentations at the 25th European Hematology Association (EHA) Annual Congress
NEW YORK , June 12, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations at the 25 th   European Hematology Association (EHA) annual congress including data from a Phase 1 study evaluating TG-1701, the Company’s once daily, selective, BTK inhibitor, as
Jun 12, 2020
TG Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
Presentation scheduled for, Thursday, June 11, 2020, at 4:40 PM ET NEW YORK , June 09, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss , the Company’s Executive Chairman and Chief Executive Officer, will participate in a fireside chat during the
Jun 09, 2020
TG Therapeutics to Present at the Jefferies 2020 Healthcare Conference
Presentation scheduled for tomorrow, Wednesday, June 3, 2020, at 10:00 AM ET NEW YORK , June 02, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss , the Company’s Executive Chairman and Chief Executive Officer, will participate in a fireside chat
Jun 02, 2020
TG Therapeutics Announces Final Results of the GENUINE Phase 3 Study Evaluating Ublituximab plus Ibrutinib in Previously Treated High-Risk Chronic Lymphocytic Leukemia at the 56th American Society of Clinical Oncology Annual Meeting
The addition of ublituximab to ibrutinib significantly improved PFS, ORR, CR rate, and increased rates of uMRD compared with ibrutinib monotherapy NEW YORK , May 29, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the final results from the GENUINE Phase 3 study
May 29, 2020
TG Therapeutics Announces Preclinical Data Presentation at the Upcoming American Association for Cancer Research Annual Meeting
NEW YORK , May 15, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that preclinical data for TG-1701, the Company’s highly selective, BTK inhibitor, has been selected for presentation at the upcoming 2020 American Association for Cancer Research (AACR) annual meeting,
May 15, 2020
TG Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
NEW YORK , May 14, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases (“the Company”), today announced the pricing of an underwritten public offering of 8,500,000 shares of common stock at a
May 14, 2020
Displaying 1 - 10 of 24